News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Knopp Biosciences And National Institutes of Health (NIH) To Collaborate In Evaluating Dexpramipexole In Patients With Hypereosinophilic Syndrome


1/8/2014 9:37:22 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

PITTSBURGH--(BUSINESS WIRE)--Knopp Biosciences LLC today announced a collaboration agreement with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to conduct a clinical trial of dexpramipexole in hypereosinophilic syndrome (HES). Under the Cooperative Research and Development Agreement (CRADA), NIAID will sponsor the Phase 2 proof-of-concept trial, while Knopp will provide the dexpramipexole study drug and will collaborate on trial design and study oversight.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES